Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT
Biotech stocks hit 52-week highs on July 9, 2026. First Track Biotherapeutics (TRAX) rose 55.99% to $32.40 on Phase 1 trial starts and an FDA end-of-Phase 2 meeting. BridgeBio Pharma (BBIO) closed at $93.52, up 15.12%, citing Acoramidis and Phase 3 plans. Monopar (MNPR), 10x Genomics (TXG) and MapLight (MPLT) also reached highs amid clinical updates.
How this was made
The 30-second read
Why it matters
The newest actionable elements are the specific upcoming milestones: Phase 1 initiation (TRAX), NDA timing (BBIO, MNPR), revenue guidance and platform launch (TXG), and topline trial timing (MPLT).
Market read
Traders can use the stated milestone dates and the TXG revenue range to frame near-term catalyst calendars and momentum risk management.
What to watch
For TRAX, BBIO, MNPR, and MPLT, the article emphasizes plans and meetings rather than disclosed efficacy/safety outcomes. For TXG, the guidance range may already be anticipated, so the market may react more to adoption metrics than to the headline range.
Background
The piece is a multi-name biotech roundup describing which stocks reached 52-week highs on July 9, 2026 and the stated catalysts behind the moves.
Ticker impact
First Tracks Biotherapeutics hit a 52-week high after initiating Phase 1 trials for ANB033 and ANB101 and concluding an end-of-Phase 2 FDA meeting for Rosnilimab.
Near-term upside bias while traders price in trial progress and FDA interaction; volatility likely around trial updates.
The article ties the 52-week high to specific clinical and regulatory milestones, but provides no new FDA decision or trial results beyond initiation/meeting.
BridgeBio reached a 52-week high as it prepares an NDA for Infigratinib in Q3 and highlighted Phase 3 results for achondroplasia.
Moderately bullish over weeks to months as NDA submission expectations build, with pullbacks possible if filing details disappoint.
The text includes concrete timing (NDA in Q3) and Phase 3 presentation, but does not disclose new FDA action or approval.
Monopar Therapeutics rose to a 52-week high with plans to submit an NDA for ALXN1840 by mid-2026 for Wilson's disease.
Bullish bias into the mid-2026 NDA window, with interim volatility around trial and regulatory communications.
The article provides a specific regulatory milestone target (mid-2026 NDA) and late-stage candidate context, but no new trial readout is stated.
10x Genomics jumped to a 52-week high after launching the Atera platform and reporting 2026 revenue guidance of $600 million to $625 million.
Likely continued support if investors treat Atera adoption and multiomics services growth as on-track; expect sensitivity to any subsequent guidance updates.
The article includes explicit revenue positioning for 2026 and a concrete product launch, both directly relevant to valuation and near-term sentiment.
MapLight Therapeutics hit a 52-week high as Phase 2 ZEPHYR topline data for ML-007C is expected in August 2026.
Bullish into August 2026 expectations, with high volatility around trial updates and FDA discussions for other programs.
The article provides a specific timing for topline data and mentions prior ML-004 failure plus planned FDA meeting, but no new ML-007C results.
Market effects
Broad biotech risk appetite appears supported by multiple company-specific clinical and regulatory catalysts, plus one name (TXG) with revenue guidance.
Primarily US-listed biotech sentiment, with Nasdaq-focused catalysts driving attention.
Limited direct global spillover; mostly company-specific development and filing timelines.
Counterpoint
52-week-high prints can reflect crowded positioning and momentum rather than new fundamental information; without fresh trial results or FDA actions, upside may fade quickly.
Key entities
- companyFirst Tracks Biotherapeutics Inc.
Clinical-stage autoimmune-focused biotech; initiated Phase 1 trials and concluded an end-of-Phase 2 FDA meeting for Rosnilimab.
- companyBridge Bio Pharma Inc.
Genetic disease and oncology biotech; preparing an Infigratinib NDA after Phase 3 results presentation.
- companyMonopar Therapeutics Inc.
Wilson's disease candidate ALXN1840; plans mid-2026 NDA submission and advances solid-tumor programs.
- company10x Genomics Inc.
Life science tools provider; launched Atera and positioned 2026 revenues at $600M to $625M.
- companyMapLight Therapeutics Inc.
Neuropsychiatry biotech; Phase 2 ZEPHYR topline data for ML-007C expected in August 2026.
